Cyrus S. Poonawalla

Poonawalla in 2015 (2nd from right) Cyrus S. Poonawalla (born in 1941) is an Indian billionaire businessman, and the chairman and managing director of the Cyrus Poonawalla Group, which includes the Serum Institute of India, an Indian biotech company which is the largest vaccine manufacturer in the world and Poonawalla Fincorp a leading NBFC in India. In 2022, he is ranked as the 4th richest person in India on Forbes India rich list with a net worth of $24.3 billion. He is ranked number 1 on the Hurun Global Healthcare Rich List 2022.

In October 2024, Poonawalla and his family were ranked ninth on Forbes list of India’s 100 richest tycoons, with a net worth of $24.5 billion. Provided by Wikipedia
Showing 1 - 6 results of 6 for search 'Cyrus S. Poonawalla', query time: 0.03s Refine Results
  1. 1
    Post-marketing safety surveillance of the rotavirus vaccine in India

    Post-marketing safety surveillance of the rotavirus vaccine in India by Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Sajjad Desai, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni

    Published 2023-12-01
    Get full text
    Article
  2. 2
    Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context

    Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context by Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Dhananjay Kapse, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni

    Published 2023-07-01
    Get full text
    Article
  3. 3
    A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine

    A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine by Sajjad Desai, K. Anil, Anirudha Vyankatesh Potey, Y. Sindhu, Silvia Grappi, Giulia Lapini, Satyaprasad Manney, Parikshit Tyagi, Emanuele Montomoli, Cyrus S. Poonawalla, Prasad S. Kulkarni

    Published 2022-12-01
    Get full text
    Article
  4. 4
    A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

    A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults by Prasad S. Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Sonali Kar, Sidram Raut, Praveen Kulkarni, Aditi Apte, Ashish Bavdekar, Hira Lal Bhalla, Joyce S. Plested, Shane Cloney-Clark, MingZhu Zhu, Raj Kalkeri, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ranga S. Sannidhi, Punjita Baranwal, Chetanraj Bhamare, Abhijeet Dharmadhikari, Manish Gupta, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, COVOVAX-Booster Study Group

    Published 2023-10-01
    Get full text
    Article
  5. 5
    Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

    Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults by Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale

    Published 2024-12-01
    Get full text
    Article
  6. 6
    Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context

    Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context by Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi

    Published 2023-03-01
    Get full text
    Article

Search Tools: